Abstract:Xianjie Yang, &ast Juan Wang, &ast Huan Wang, Minmin Kong, Qiquann Chen Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Qiquann Chen, Email Acute generalized pustular psoriasis (GPP) is a severe but rare variant of psoriasis, characterized by an acute eruption of extensive erythema with numerous non-follicular pustules. In rare cases, local pustular psoriasis like acrodermatitis continua of Hallopeau (ACH) may progress into acute GPP if improperly treated. ACH and GPP are rare in the clinic and their treatment is more complex and often treatment-resistant compared to psoriasis vulgaris (PV). A variety of anti-psoriasis biologics emerging in recent years have been reported for the treatment of ACH and acute GPP. Biologics is considered to be an upgraded treatment option for traditional anti-psoriasis agents. But there are few reports of GPP patients developing resistance to biologics, or what if biologics fails. Herein, we report a case of acute GPP that developed from ACH, initially responded extremely well to adalimumab, but the treatment failed when the patient treated with the drug again, which is thought to have developed resistance to adalimumab, finally successfully treated with narrowband ultraviolet B (NB-UVB) and acitretin. Keywords: acute generalized pustular psoriasis, acrodermatitis continua of hallopeau, adalimumab, narrowband ultraviolet B, acitretin Generalized pustular psoriasis (GPP), which manifests as an acute or subacute, widely distributed eruption of pustules arising on inflamed, erythematous skin, is a severe but rare variant of psoriasis. This rare condition affects male and female of all ages, including infants, children, and adolescents, but mostly affects adults. 1 The aetiology of GPP is not fully delineated. Many patients with GPP may have a preceding history of another form of psoriasis, and some GPP may develop from local pustular psoriasis like acrodermatitis continua of hallopeau (ACH) or palmoplantar pustulosis (PPP). The severe GPP flare cause a dramatic reduction in quality of life and even has potentially life-threatening. Very few drugs have been approved specifically for the treatment of GPP. Biologics approved for PV, such as tumor necrosis factor (TNF)-alpha inhibitors (including infliximab, adalimumab and etanercept), anti-interleukin (IL) 17 (ixekizumab and secukinumab) and anti-IL-23 (ustekinumab) biologic agents, have been adopted for the treatment of GPP. 2 Although there are more and more reports on the treatment of GPP with these biologics, there are few reports on their treatment failure, and no attention has been paid to what to do if the biologics fail. Besides, treatment options for pediatric GPP are more limited and few drugs are approved for use, but adalimumab is one of the therapy approved by FDA. Herein, we report a rare case of acute GPP that developed from ACH, initially responded extremely well to adalimumab, but the treatment failed because the patient did not administrate the biologics on time and developed resistance to it, finally successfully treated with narrowband ultraviolet B (NB-UVB) and acitretin. A 14-year-old adolescent female was referred to our department in July 2021 with generalized pustular and erythematous on the trunk and extremities for a week. She did not complain of chills, fever or arthralgia, but complained of swelling and pain and mild itching in the lesions. During the history collection, the patient reported a history of recurrent pustules on the distal portion of the middle finger of her right hand since 2015, which had been diagnosed as onychomycosis and treated with oral and topical antifungal in local hospitals for half a year but failed in 2017. In the summer of 2019, pustules gradually developed to multiple fingers of her both hands (Figure 1A), she visited our clinic and had a biopsy, bacterial culture was sterile and the pathologic results confirmed the diagnosis of ACH (Figure 1B and C). Since then she received intermittently treatment with oral thiamphenicol, compound glycyrrhizin, minocycline, and traditional Chinese medicine (TCM), and so on, combined with topical halometasone and tazarotene cream. The treatment response was still poor and more fingers were involved. She returned to our out-patient three months ago. According to the patient's previous treatment response, in order to improve the treatment effect, taking into account the patient's age and economic status, oral cyclosporine (150mg/day, 4mg/kg/day) was given, but there was no improvement after one month of adherence, so she stopped the medication on her own. However, about half a month after she stopped cyclosporine, the symptoms of her fingers became -Abstract Truncated-

Adalimumab-Induced Erythrodermic Psoriasis Associated with Alopecia in a Patient with Palmoplantar Pustulosis

Successful Treatment of a Patient with Pyoderma Gangrenosum, Plaque Psoriasis and Palmoplantar Pustulosis with Adalimumab

A case of systemic lupus erythematosus complicated with pemphigus vulgaris

Adalimumab induced exacerbation of psoriasis in patients with combined pemphigus: A case report

Adalimumab induced psoriasis in a Crohn's disease patient: A case report

Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab

Case report: Treatment of psoriasiform dermatitis in patients with malignancy

Atypical Dermatitis Herpetiform and Scalp Psoriasis in Ulcerative Colitis Patient Treated With Adalimumab

Successful Treatment of Secukinumab-Resistant Palmoplantar Pustulosis by Dupilumab: A Case Report.

A case of subacute thyroiditis in a patient on adalimumab for treatment of refractory palmo-plantar psoriasis

Uveitis occurring in a patient with psoriasis during adalimumab therapy: A case report

Anemia and Thrombocytosis Associated with Erythrodermic Psoriasis Successfully Treated with Ixekizumab: A Case Report

Efficacy and Safety of Adalimumab in Chinese Patients with Moderate-To-Severe Plaque Psoriasis: Results from A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study

Erythrodermic psoriasis and palmoplantar hyperkeratosis successfully treated with secukinumab: a case report

Upadacitinib Efficacy for the Treatment of Concomitant Psoriasis and Alopecia Areata

Efficacy of Dupilumab in Palmoplantar Pustulosis Treatment Highlights the Role of Th2 Inflammation.

Acute Generalized Pustular Psoriasis Developed Resistance to Adalimumab Was Successfully Treated with Narrowband Ultraviolet B and Acitretin: A Case Report

Combination of secukinumab and acitretin for generalized pustular psoriasis: A case report and review of literature

A Case Report of Majocchi's Granuloma Associated with Combined Therapy of Topical Steroids and Adalimumab

Atezolizumab-Induced Acrodermatitis and Pustular Psoriasis in a Patient with Non-Small Cell Lung Cancer: A Rare Case Report

Lichenoid Drug Eruption Secondary to Adalimumab: A Case Report